Pulmonary emphysema or emphysema is a chronic respiratory disease characterized by damage to the air sacs (alveoli) in the lungs leading to shortness of breath. Some common symptoms of emphysema include shortness of breath, persistent coughing, wheezing, chest tightness, frequent respiratory infections, fatigue, and weight loss. Emphysema has no known cure and is usually treated via drugs, oxygen therapy, pulmonary rehabilitation, lung volume reduction surgery, and lung transplant in severe cases. Pulmonary rehabilitation devices such as bronchodilators, breathing exercises equipment, and portable oxygen concentrators have shown significant effectiveness in managing emphysema symptoms.
The global emphysema market is estimated to be valued at US$ 7.2 Billion in 2028 and is expected to exhibit a CAGR of 3.8% over the forecast period 2028-2033.
Key Takeaways
Key players operating in the Emphysema Market are GlaxoSmithKline plc, Roche, Pfizer Inc., Abbott Laboratories, and Boehringer Ingelheim GmbH.
Key opportunities in the market include growing geriatric population who are more susceptible to chronic respiratory diseases and increasing willingness to adopt innovative emphysema treatment devices.
Advancements in portable oxygen concentrators, ventilators, and other pulmonary rehabilitation devices have vastly improved treatment outcomes for emphysema patients allowing them to lead more productive lives. Wearable technology incorporated in breathing exercise equipment has also made rehabilitation more accessible and convenient.
Market Drivers
High prevalence of chronic respiratory diseases globally is a major factor driving the emphysema market. Emphysema incidence has increased in recent years due to rising air pollution levels, tobacco smoking, and aging population. Growing awareness about availability of effective emphysema treatment options is also compelling more patients to seek medical help rather than ignore symptoms previously. This is positively impacting the market revenues.
Current Challenges in Emphysema Market
The emphysema market is facing various challenges currently. The treatment for emphysema is largely symptomatic which provides only temporary relief from the symptoms. There is no cure available for emphysema and the condition can only be managed. This poses a major challenge for patients suffering from emphysema. Another major challenge is lack of awareness about emphysema especially in developing nations. Many people mistake the symptoms for other conditions like asthma or COPD. This results in delayed diagnosis and treatment further increasing the health risks. High treatment costs also pose affordability challenges especially for patients in Low and middle income countries.
SWOT Analysis
Strength: Presence of several treatment options covering medication, therapy and surgery provides alternatives for symptom management and improving lung function.
Weakness: Absence of a complete cure makes emphysema a lifelong condition and repetitive treatments are required. Research on regenerative therapies is still at an early stage.
Opportunity: Advances in lung transplantation and regenerative medicine research provide scope for newer treatment avenues. Increased awareness can help improve early diagnosis.
Threats: Rising pollution and smoking especially in developing world is increasing the patient base. High treatment expenses throughout the disease progression poses financial burden.
Europe accounts for the largest share in the global emphysema market in terms of value. The region has reported high prevalence of emphysema cases backed by aging population and high smoking rates. North America is the second largest market driven by availability of advanced treatment options and presence of major players.
The Asia Pacific region is expected to witness fastest growth in the emphysema market over the forecast period. This can be attributed to improving healthcare infrastructure, increasing disposable incomes, growing awareness about respiratory diseases and rising pollution in densely populated countries such as India and China.
What Are The Key Data Covered In This Emphysema Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Emphysema’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Emphysema and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Emphysema Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Emphysema vendors
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it